This is a rare type of acute leukemia that has features of both the myeloid and lymphoid types of white blood cells. It arises from stem cells.
Every report comes from a Lived member, sent anonymously.
Have you had Stem Cell Transplant for Acute Biphenotypic Leukemia?
Acute biphenotypic leukemia, now usually called mixed-phenotype acute leukemia (MPAL), is a rare blood cancer in which the leukemia cells carry features of two different families of white blood cells at once. Most acute leukemias are clearly one type or the other: acute lymphoblastic leukemia (ALL) comes from immature lymphoid cells, and acute myeloid leukemia (AML) comes from immature myeloid cells. In MPAL, the abnormal immature cells (blasts) show markers of both, either within the same cells or as two separate groups of cells. Like other acute leukemias, MPAL starts in the bone marrow and tends to worsen quickly without treatment. The leukemia cells crowd out normal blood production, which can cause tiredness, shortness of breath, fevers or infections, and easy bruising or bleeding. Compared with other acute leukemias, swollen lymph nodes, an enlarged liver or spleen, and spread to the brain and spinal cord are somewhat more common at diagnosis. MPAL accounts for only a few percent of acute leukemias, and it matters to identify it because the mixed nature of the disease shapes how it is treated.
The cause of MPAL is not known. In most people, the leukemia cells carry acquired changes in their chromosomes or genes, often several at once. These changes develop in blood-forming cells during a person's life; they are usually not inherited and are not caused by anything the person did. Researchers are still debating exactly how a single leukemia comes to show features of two cell families. MPAL can occur in children and adults and is slightly more common in men. Some genetic changes define recognized subtypes, most notably the Philadelphia chromosome (a swap between chromosomes 9 and 22 that creates the BCR::ABL1 gene) and rearrangements of a gene called KMT2A. These matter less as causes than as clues to which treatment is likely to work.
Diagnosis usually begins with a complete blood count showing abnormal white blood cell levels, low red cells or low platelets, and a blood smear showing blasts. A bone marrow test is then needed, in which a needle removes a small sample of liquid marrow and a sliver of bone for testing. The key test for MPAL is immunophenotyping, most often by flow cytometry, which reads the proteins (markers) on the surface and inside the leukemia cells. MPAL is diagnosed when specific markers of two lineages are clearly present, using international classification criteria. This is technically demanding, and some leukemias look mixed but are classified as AML instead, for example when they arise after earlier chemotherapy or carry certain defining genetic changes. A review by a specialized hematopathology lab is therefore valuable. Chromosome and gene testing of the leukemia cells identifies subtypes such as Philadelphia-positive MPAL, and a lumbar puncture (spinal tap) checks whether leukemia cells are present in the fluid around the brain and spinal cord.
There is no single standard treatment for MPAL, because it is rare and has not been studied in large prospective trials. The approach most specialists favor, based on retrospective studies, is chemotherapy designed for acute lymphoblastic leukemia (ALL-type therapy). Treatment starts with induction, an intensive phase that aims to clear leukemia from the blood and bone marrow and achieve remission, followed by further phases to destroy remaining cells and prevent relapse. Chemotherapy is also given into the spinal fluid to treat or prevent leukemia in the brain and spinal cord. Treatment is adjusted to the leukemia's genetics. For Philadelphia-positive MPAL, a targeted pill called a tyrosine kinase inhibitor, such as imatinib, is added to chemotherapy and improves outcomes. If the leukemia does not respond well to ALL-type therapy, doctors commonly switch to AML-type chemotherapy, or the reverse. Combining both types from the start was linked to worse survival in one large analysis, possibly because of added toxicity, although newer hybrid regimens are being studied. An allogeneic stem cell transplant, which replaces the person's blood-forming system with cells from a matched donor, is the main way to reduce relapse in adults. Adults are generally advised to have a transplant during their first remission if a suitable donor is available. Children often do well with ALL-type chemotherapy alone, so transplant is usually reserved for those whose leukemia responds slowly or comes back. For older adults who cannot tolerate intensive chemotherapy, gentler combinations such as venetoclax (a targeted cancer pill) with a hypomethylating drug have produced remissions in small reports. Newer immune-based treatments used in ALL are also being explored, mainly when leukemia returns. Clinical trials are an important option for this disease.
Treatment is intensive and usually begins soon after diagnosis, often with a hospital stay during induction. During chemotherapy, blood counts drop, so infections, transfusions of red cells or platelets, fatigue and missed work or school are common. ALL-type treatment continues in phases over many months, and a transplant adds its own preparation, hospital stay and recovery period. The outlook varies widely. MPAL has historically had poorer results than standard-risk AML or ALL, and adults generally fare worse than children. A key guide to prognosis is measurable residual disease (MRD), a very sensitive test of how many leukemia cells remain after treatment; a fast drop to very low or undetectable levels is a good sign, while persistent MRD often leads to a change in treatment or a transplant. The genetic subtype also matters. After treatment ends, regular blood tests and visits check whether the leukemia has come back. Long-term follow-up also watches for late effects of treatment, which can appear months or years later and include a risk of second cancers.
See a clinician the same day for unexplained ongoing tiredness with pale skin, easy bruising or tiny red spots on the skin, frequent or lingering infections, or bone pain, since acute leukemia can progress quickly and a simple blood count can screen for it. During treatment, contact the cancer care team right away, day or night, for a fever of 100.5 F (38 C) or higher, shaking chills, or redness or swelling where a catheter enters the body. Infections while white cell counts are low can become life threatening quickly, and the team will tell you whether to come in. Do not take fever-lowering medicine before calling, since it can hide a fever.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Acute Biphenotypic Leukemia is like, what's helped you, or ask the community a question.